Print

MediciNova, Inc. Receives New Patent Covering MN-221 In Irritable Bowel Syndrome  
11/12/2013 12:45:02 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Nov. 11, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that a new U.S. patent has been granted which covers MN-221 in the treatment of irritable bowel syndrome.

Help employers find you! Check out all the jobs and post your resume.

//-->